Estimating the Impact of Plasma HIV-1 RNA Reductions on Heterosexual HIV-1 Transmission Risk

Background The risk of sexual transmission of HIV-1 is strongly associated with the level of HIV-1 RNA in plasma making reduction in HIV-1 plasma levels an important target for HIV-1 prevention interventions. A quantitative understanding of the relationship of plasma HIV-1 RNA and HIV-1 transmission risk could help predict the impact of candidate HIV-1 prevention interventions that operate by reducing plasma HIV-1 levels, such as antiretroviral therapy (ART), therapeutic vaccines, and other non-ART interventions. Methodology/Principal Findings We use prospective data collected from 2004 to 2008 in East and Southern African HIV-1 serodiscordant couples to model the relationship of plasma HIV-1 RNA levels and heterosexual transmission risk with confirmation of HIV-1 transmission events by HIV-1 sequencing. The model is based on follow-up of 3381 HIV-1 serodiscordant couples over 5017 person-years encompassing 108 genetically-linked HIV-1 transmission events. HIV-1 transmission risk was 2.27 per 100 person-years with a log-linear relationship to log10 plasma HIV-1 RNA. The model predicts that a decrease in average plasma HIV-1 RNA of 0.74 log10 copies/mL (95% CI 0.60 to 0.97) reduces heterosexual transmission risk by 50%, regardless of the average starting plasma HIV-1 level in the population and independent of other HIV-1-related population characteristics. In a simulated population with a similar plasma HIV-1 RNA distribution the model estimates that 90% of overall HIV-1 infections averted by a 0.74 copies/mL reduction in plasma HIV-1 RNA could be achieved by targeting this reduction to the 58% of the cohort with plasma HIV-1 levels ≥4 log10 copies/mL. Conclusions/Significance This log-linear model of plasma HIV-1 levels and risk of sexual HIV-1 transmission may help estimate the impact on HIV-1 transmission and infections averted from candidate interventions that reduce plasma HIV-1 RNA levels.

[1]  James P. Hughes,et al.  Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. , 2010, The New England journal of medicine.

[2]  T. Quinn,et al.  Determinants of HIV-1 load in subjects with early and later HIV infections, in a general-population cohort of Rakai, Uganda. , 2004, The Journal of infectious diseases.

[3]  Christopher Dye,et al.  Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model , 2009, The Lancet.

[4]  T. Quinn,et al.  Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. , 2000, The New England journal of medicine.

[5]  S. Vermund,et al.  Virologic and immunologic determinants of heterosexual transmission of human immunodeficiency virus type 1 in Africa. , 2001, AIDS research and human retroviruses.

[6]  Christophe Fraser,et al.  HIV-1 transmission, by stage of infection. , 2008, The Journal of infectious diseases.

[7]  Christophe Fraser,et al.  Estimating the public health impact of the effect of herpes simplex virus suppressive therapy on plasma HIV-1 viral load , 2009, AIDS.

[8]  J. Overbaugh,et al.  Albendazole treatment of HIV-1 and helminth co-infection: a randomized, double-blind, placebo-controlled trial , 2008, AIDS.

[9]  Connie Celum,et al.  Herpes simplex virus (HSV) suppression with valacyclovir reduces rectal and blood plasma HIV-1 levels in HIV-1/HSV-2-seropositive men: a randomized, double-blind, placebo-controlled crossover trial. , 2007, The Journal of infectious diseases.

[10]  Joep Lange,et al.  The spread, treatment, and prevention of HIV-1: evolution of a global pandemic. , 2008, The Journal of clinical investigation.

[11]  H. Rees,et al.  Impact of aciclovir on genital and plasma HIV-1 RNA in HSV-2/HIV-1 co-infected women: a randomized placebo-controlled trial in South Africa , 2009, AIDS.

[12]  Wendy S Stevens,et al.  Challenges in implementing HIV load testing in South Africa. , 2010, The Journal of infectious diseases.

[13]  Vincent Foulongne,et al.  Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus. , 2007, The New England journal of medicine.

[14]  S. Vermund,et al.  Effect of treating co-infections on HIV-1 viral load: a systematic review. , 2010, The Lancet. Infectious diseases.

[15]  J. Baeten,et al.  Herpes simplex virus (HSV)-suppressive therapy decreases plasma and genital HIV-1 levels in HSV-2/HIV-1 coinfected women: a randomized, placebo-controlled, cross-over trial. , 2008, The Journal of infectious diseases.

[16]  S. Vermund,et al.  Impact of small reductions in plasma HIV RNA levels on the risk of heterosexual transmission and disease progression , 2008, AIDS.

[17]  O. Laeyendecker,et al.  Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. , 2005, The Journal of infectious diseases.

[18]  T. Merigan,et al.  Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group. , 1996, The New England journal of medicine.

[19]  S. Whitehead,et al.  Suppressive Acyclovir Therapy Reduces HIV Cervicovaginal Shedding in HIV- and HSV-2-Infected Women, Chiang Rai, Thailand , 2008, Journal of acquired immune deficiency syndromes.

[20]  References , 1971 .

[21]  D. Ho,et al.  A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. , 1995, The New England journal of medicine.

[22]  S. Gurunathan,et al.  Use of predictive markers of HIV disease progression in vaccine trials. , 2009, Vaccine.

[23]  T. Quinn,et al.  The Effects of Herpes Simplex Virus-2 on HIV-1 Acquisition and Transmission: A Review of Two Overlapping Epidemics , 2004, Journal of acquired immune deficiency syndromes.